Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 6645 record(s)

Req # A-2024-001189

Adverse Drug Reactions (ADRs). Report numbers: E2B_07458564, E2B_07467813.

Organization: Health Canada

1733 page(s)
January 2025

Req # A-2024-001191

Adverse Drug Reactions (ADRs). Report numbers: 001100939, 001103018, 001104642, E2B_07208128, E2B_07241676.

Organization: Health Canada

18 page(s)
January 2025

Req # A-2024-001192

Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_07470391. ADRs for Entyvio. Report numbers: E2B_07461648, E2B_07452627, 001110995, E2B_07490527. ADRs for Lisdexamfetamine dimesylate. Report numbers: E2B_07494414, E2B_07458121,…

Organization: Health Canada

1014 page(s)
January 2025

Req # A-2024-001193

Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: 001119129, E2B_07504484, 001112118, E2B_07504969, E2B_07502047, 001109962, 001112788. ADRs for Immunoglobulin (human). Report numbers: E2B_07485309, E2B_07497976, E2B_07459838.

Organization: Health Canada

181 page(s)
January 2025

Req # A-2024-001196

Adverse Drug Reaction (ADR) for Amphetamine aspartate monohydrate/ amphetamine sulfate/ dextroamphetamine saccharate/ dextroamphetamine sulfate. Report number: 001110987. ADR for Mesalazine. Report number: E2B_07475683. ADRs for C1 Esterase…

Organization: Health Canada

107 page(s)
January 2025

Req # A-2024-001199

Adverse Drug Reaction (ADR). Report number: 001105120.

Organization: Health Canada

2 page(s)
January 2025

Req # A-2024-001206

Adverse Drug Reactions (ADRs). Report numbers: E2B_07490565, 001108811, 001124193, 001117067.

Organization: Health Canada

69 page(s)
January 2025

Req # A-2024-001208

Adverse Drug Reactions (ADRs). Report numbers: 001103378, 001101755, 001104894, 001104628, 001102411, 001101188, 001102208, E2B_07385877, E2B_07358095, E2B_07412651.

Organization: Health Canada

1241 page(s)
January 2025

Req # A-2024-001212

Adverse Drug Reaction (ADR). Report number: E2B_07231496.

Organization: Health Canada

18 page(s)
January 2025

Req # A-2024-001226

Adverse Drug Reaction (ADR) for Alburex-5. Report number: 001076913.

Organization: Health Canada

14 page(s)
January 2025
Date modified: